Altre lingue Johnson & Johnson Börse Stuttgart

Azioni

JNJ

US4781601046

Tempo reale stimato Tradegate Altri mercati azionari 08:26:45 12/07/2024			Variaz. 5gg	Var. 1 gen.
138 ^EUR	+0,38%		+1,82%	-2,83%

11/07	Johnson & Johnson completa l'acquisizione di Yellow Jersey Therapeutics	MT
09/07	Emergent Biosolutions, Johnson & Johnson risolvono la controversia sulla produzione del vaccino COVID-19	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics	11/07
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26	11/07
Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)	10/07
Mixed feelings	09/07
EEUU - Valores a seguir en Wall Street (actualizado)	09/07
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing	09/07
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9)	09/07
Emergent, J&J settle COVID vaccine supply deal dispute	08/07
Emergent Biosolutions to Get $50 Million from Covid-19 Manufacturing Settlement with Johnson & Johnson Unit	08/07
J&J to pay $50 million to Emergent to resolve manufacturing deal for COVID vaccine	08/07
The battle over J&J's bankruptcy plan to end talc lawsuits	08/07
Stryker Corporation : Major Player in Medical Devices	06/07
Momentum Picks Q3/ 2024: 5 Aktien für den Sommer	03/07
Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	03/07
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	03/07
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	03/07
J&J : approbation complète pour Sirturo dans la tuberculose	03/07
Momentum Picks Q3 2024: vijf aandelen voor de zomer	02/07
Momentum Picks T3 2024: 5 valores para el verano	02/07
J&J : résultats prometteurs dans le myélome multiple	02/07

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

La pipeline di farmaci è ben posizionata per il 2024, dice il CFO di J&J

23 gennaio 2024 alle 18:30